Finance entity
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Cedar Fair, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline.
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Cedar Fair, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. Insmed appears in 1 tracked Finance story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 174 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Insmed. Shared-story counts are live from our verified record — not editorial picks.
Investors are bracing for pivotal Q4 2025 earnings reports from amusement park giant Six Flags (Legacy Cedar Fair) and biotech firm Insmed. While Six Flags navigates the complexities of its recent mega-merger, Insmed is focused on the commercial scaling of its lead therapy and the regulatory path for its pipeline.
Insmed is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
